Drug Innovations, Higher Margins and Improving Standards of Clinical Research - Research Report on Quest Diagnostics, Trius,

Drug Innovations, Higher Margins and Improving Standards of Clinical Research
   - Research Report on Quest Diagnostics, Trius, WuXi, Quintiles, and ICON

PR Newswire

NEW YORK, August 15, 2013

NEW YORK, August 15, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Quest
Diagnostics Inc. (NYSE: DGX), Trius Therapeutics, Inc. (NASDAQ: TSRX), WuXi
PharmaTech (Cayman) Inc. (NYSE: WX), Quintiles Transnational Holdings Inc.
(NYSE: Q), and ICON plc (NASDAQ: ICLR). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Quest Diagnostics Inc. Research Report

On August 8, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that
its new genetic test to assist in the delivery of personalized opioid
pain-relieving treatment is available. "Genetic testing to personalize the use
of pain-alleviating drug therapies is an exciting new clinical field with
tremendous potential to promote favorable outcomes for the many millions of
individuals struggling with pain," said Charles (Buck) Strom, MD, PhD, Senior
Medical Director, Genetics, Quest Diagnostics. Strom added, "The inclusion of
Transgenomic's gene discoveries into our genetic testing services will provide
physicians with greater insights for safely and effectively administering
opioid treatment." According to Quest Diagnostics, it is believed to be the
first clinical lab to offer testing for variants in all cytochrome P450
(CYP450) genes known to influence the CYP450 enzyme system, which affects
metabolism of opioids and other medications. The Full Research Report on Quest
Diagnostics Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/05ba_DGX]

Trius Therapeutics, Inc. Research Report

On August 6, 2013, Trius Therapeutics, Inc. (Trius) reported its Q2 2013
financial results with total revenues of $1.3 million compared to $6.2 million
in Q2 2012. Further, the Company reported an increase in net loss to $19.7
million, or $0.41 per diluted share, compared to net loss of $14.4 million, or
$0.37 per diluted share, in Q2 2012, and the increase in net loss was
primarily attributable to lower collaboration revenues and federal contracts.
R&D expenses increased to $14.7 million in Q2 2013 from $16.4 million in Q2
2012 primarily due to lower clinical and development costs for tedizolid
phosphate. Further, the Company plans to submit New Drug Applications (NDA)
for the oral and intravenous dosage forms of tedizolid phosphate to the US
Food and Drug Administration (FDA) in the second half of 2013. The Full
Research Report on Trius Therapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/15b0_TSRX]

WuXi PharmaTech (Cayman) Inc. Research Report

On August 12, 2013, WuXi PharmaTech Inc. (WuXi) reported its unaudited Q2 2013
financial results with reported net revenue growth of 9.2% YoY to $142.3
million. Net income increased 44.6% YoY to $29.6 million during the quarter.
GAAP diluted EPS increased 45.5% YoY to $0.41. "By serving our customers well,
we are achieving solid, broad-based revenue growth," said Dr. Ge Li, Chairman
and Chief Executive Officer. "We exceeded our second-quarter 2013 revenue
guidance, driven by excellent performances by China-based Laboratory Services
and Manufacturing Services. We also exceeded our second-quarter 2013 EPS
guidance. Year-over-year GAAP diluted EPS growth of 45.5% benefited from this
revenue performance, gross margin improvement, large mark-to-market gains from
foreign-exchange forward contracts, and lower tax expense." The Company
increased its full-year 2013 revenue guidance to $572 million to $578 million
and GAAP diluted EPS guidance to $1.38 to $1.44. The Full Research Report on
WuXi PharmaTech (Cayman) Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/df7b_WX]

Quintiles Transnational Holdings Inc. Research Report

On August 1, 2013, Quintiles Transnational Holdings Inc. (Quintiles) reported
its Q2 2013 financial results with service revenues declining 0.1% YoY to
$944.2 million. Adjusted net income totaled $62.9 million, up 12.6% YoY.
Diluted adjusted EPS stood at $0.50, up 6.4% YoY. "Quintiles delivered solid
results overall with continued strength in new business wins," said Tom Pike,
Quintiles' Chief Executive Officer. I am also pleased to report double-digit
adjusted net income growth and improved margins on a year-to-date basis
despite the negative impact on revenues that resulted from unfavorable foreign
exchange rates." The Company expects its service revenues for 2013 to be in
the range of $3.76 billion to $3.81 billion and diluted adjusted EPS to be in
the range of $1.95 to $2.05. The Full Research Report on Quintiles
Transnational Holdings Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9f5c_Q]

ICON plc Research Report

On August 7, 2013, ICON Plc, (ICON) announced a collaboration agreement with
the National Clinical Trials and Research Centre (NCTRC) to enhance set-up and
management of clinical studies in Taiwan. Under the terms of the agreement,
both organizations will collaborate on study start-up, site feasibility, key
site and investigator selection and patient recruitment as well as improve the
standards of clinical research in Taiwan. "We are very pleased to be
collaborating with the NCTRC who are at the forefront of clinical research in
Taiwan," commented Wei Ming Goh, ICON's Vice President, Asia-Pacific. "By
combining the proven expertise of ICON and NCTRC in the region, we can further
accelerate study timelines which will benefit our customers and also enhance
the Taiwanese clinical trials industry." The Full Research Report on ICON plc
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/fbb0_ICLR]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    making mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)